Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

BioXcel Therapeutics

  • Vimal Mehta, BioXcel Therapeutics

BioXcel Therapeutics is a clinical stage biopharmaceutical company focused on drug development in neuroscience and immuno-oncology utilizing artificial intelligence. Currently the company has two lead clinical development programs:

o BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders

• Reported positive results from Phase 1b trial of intravenously-dosed Dexmedetomidine supporting BXCL501 development in schizophrenia

• Data from Phase 1b PK/PD safety study in mild probable Alzheimer’s patients expected in second half of 2018

o BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer

• Announced FDA acceptance of IND for treatment emergent neuroendocrine prostate cancer; study expected to be initiated in fourth quarter of 2018

• Entered clinical partnership with Nektar for study in pancreatic cancer

  • Date:Monday, February 11
  • Time:3:00 PM - 3:15 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23353
  • Goal for Presentation:Corporate Overview and Future Plans
  • Company Website:http://www.bioxceltherapeutics.com/
  • Company HQ City:New Haven
  • Company HQ State:Connecticut
  • Company HQ Country:United States
  • Ticker:BTAI
  • Exchange:Nasdaq
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:BXCL501 and BXCL701
  • Development Phase of Primary Product:Phase I
Speakers
Vimal Mehta
BioXcel Therapeutics
Back